Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, January 19, 2022
Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the launch of its new Xpress ...
read more
Wednesday, August 12, 2020
Catalent announced that it has been approved by the FDA to produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy.
read more
Monday, November 01, 2021
Catalent, a global leader in clinical supply services, today announced the opening of a new facility in San Diego, in response to increased demand from pharmaceutical and biopharmaceutical customers for integrated development, clinical packaging, and...
read more
Friday, February 27, 2015
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has today announced several expanded capabilities within its European Clinical ...
read more
Catalent announced the completion of a $3.2 million expansion program at its consumer health manufacturing facilities in Strathroy, Canada and Sorocaba, Brazil.
read more
Tuesday, October 24, 2017
Catalent has completed the acquisition of Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services.
read more
Catalent has completed the $1.2 billion acquisition of Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies.
read more
Tuesday, January 25, 2022
Catalent announced that it has completed a $10 million expansion in state-of-the-art large-scale isolator units at its Malvern, Pennsylvania, and Dartford, U.K., facilities, to provide advanced containment capabilities for the micronization of highly...
read more
Catalent announced it began Phase 2 clinical trials of MGB Biopharma.
read more
Catalent Pharma Solutions has signed a multi-year agreement with Grid Therapeutics, for the development and manufacture of Grid’s lead therapeutic candidate for the treatment of solid tumors.
read more
Catalent held a ground breaking ceremony at its Bloomington, Indiana site to mark the start of construction on a $112 million drug product manufacturing facility.
read more
Catalent plans to invest $30 million at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.
read more
Catalent announced the launch of a next-generation cell line development technology, GPEx® Lightning. Leveraging Catalent’s proven GPEx expression platform in a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line system, GPEx ...
read more
Thursday, September 03, 2020
Catalent announced it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, Indiana, facility.
read more
Thursday, January 22, 2015
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Mitsubishi Gas Chemical Company, Inc. (MGC), today jointly announced that they ...
read more